Our study demonstrated that treatment with RAF/MEK targeting agents and initial tumor shrinkage are independent factors associated with improved survival in patient with mutant BRAF. These findings support data from a series of published individual studies with molecules including but not limited to PLX4032, GSK2118436 (BRAF inhibitor), and GSK 1120212 (MEK1/2 inhibitor) in mutBRAF cancer [3]–[6]. Here, MAP2K7 is linked to cancer.